Shares plunged 8.4% to $3.18 after hours as Niagen Bioscience's second-quarter results exposed a widening crack between the company's fastest-growing channel and the rest of its business. Total net sales came in at $29.8 million, including $24.2 million from its flagship Tru Niagen supplement.

That missed the analyst consensus by 0.55% and represented a decline from $31.1 million a year ago — a troubling reversal for a firm that guided to 10–15% full-year growth.

  • The Ingredient Business Is Bleeding, and Competitors Are Why. The business-to-business ingredient segment brought in just $5.4 million.

That division was "softer," with revenue weighed down by lower purchases from a key partner, Life Extension, and growing competition from rival ingredients NMN and NAD. This matters because ingredient sales carry less marketing cost than consumer products — when they shrink, the company has to spend more to make up the gap elsewhere.

  • Strong Online Sales Can't Paper Over the Top-Line Decline. Website direct sales grew 23% year-over-year, while Amazon sales rose 10%.

Combined e-commerce revenue hit $20.5 million, up 14% — or roughly 19% excluding a temporary Amazon listing disruption. Yet total revenue still fell year-over-year. That math tells investors the non-e-commerce business is contracting fast enough to overwhelm the online gains.

  • Profits Collapsed Even as Margins Held. Gross margin stayed solid at 64.8%, but net income fell to just $1.0 million ($0.01 per share).

A year ago, the company earned $3.6 million. The culprit: selling and marketing expense surged to 34% of sales, up from 26.4% a year earlier , as management poured money into new channels including telehealth and skincare. Investors are effectively being asked to fund a transformation with no near-term payoff.

  • Wall Street Remains Bullish, But the Stock Disagrees. All five covering analysts rate NAGE a "Strong Buy" with an average 12-month price target of $13.60 — more than four times today's price. Yet the stock has lost about 44.5% since the start of the year versus the S&P 500's 11% gain.

The balance sheet offers a cushion — $66.7 million in cash and $2.8 million in buybacks this quarter — but cash alone won't close a credibility gap this wide. Until ingredient revenue stabilizes and the spending surge translates into revenue, the disconnect between analyst targets and the market's verdict will persist.